Natl Toxicol Program Tech Rep Ser. 1990 Mar;340:1-171.
Toxicology and carcinogenesis studies of iodinated glycerol (Organidin(R)., a complex mixture prepared by the reaction of iodine with glycerol and found to contain 33% 3-iodo-1,2-propanediol as the major component) were conducted because of human exposure to iodinated glycerol as an expectorant and its possible relationship to the formation of alkyl iodides, e.g., methyl iodide, a suspected animal carcinogen. These studies were conducted by giving iodinated glycerol in water by gavage (5 days per week) to groups of F344/N rats and B6C3F1 mice for 16 days, 13 weeks, or 2 years. Genetic toxicology studies were conducted with iodinated glycerol in Salmonella typhimurium, mouse L5178Y lymphoma cells, Chinese hamster ovary (CHO) cells, and B6C3F1 mice (in vivo bone marrow micronucleus test). Also, 3-iodo-1,2-propanediol was tested in S. typhimurium and B6C3F1 mice (in vivo micronucleus assay). Sixteen-Day and Thirteen-Week Studies: Sixteen-day studies were conducted by giving iodinated glycerol at doses up to 1,000 mg/kg to rats and up to 500 mg/kg to mice. All female rats and 4/5 male mice in the highest dose group died before the end of the studies; there were no dose-related effects on body weights of male or female rats or male mice at the end of the studies. The forestomach of 2/5 female mice that received 500 mg/kg was thickened and granular. Thirteen-week studies were conducted by administering iodinated glycerol at doses up to 500 mg/kg to rats and mice. During these studies, 3/10 female rats and 1/10 female mice that received 500 mg/kg died. Final mean body weights of rats and mice that received 500 mg/kg were 4% lower than those of vehicle controls for males and 6%-7% lower for females. Kidney tubular cell lesions, including cortical necrosis, regeneration, and calcification, were observed at increased incidences in the highest dose group of female rats. Lymphoid hyperplasia of the stomach was observed in dosed male and female rats. Kidney tubular cell regeneration was also observed in dosed female mice. Inflammation or abscesses of mild-to-moderate severity and hyperplasia, acanthosis, and/or hyperkeratosis of mild-to-moderate severity were observed in the forestomach of the highest dosed group of female mice. Body Weight and Survival in the Two-Year Studies: Two-year studies were conducted by administering 0, 125, or 250 mg/kg iodinated glycerol in deionized water by gavage, 5 days per week for 103 weeks, to groups of 50 male F344/N rats and 50 male B6C3F1 mice. Groups of 50 female F344/N rats and 50 female B6C3F1 mice were administered iodinated glycerol on the same schedule at lower doses of 0, 62, or 125 mg/kg because of the increased severity of kidney and stomach lesions in the 13-week studies. Mean body weights of high dose male rats were 5%-10% lower than those of vehicle controls from week 43 to week 68 and 10%-13% lower from week 72 to the end of the studies. Mean body weights of low dose male rats and high dose female rats were 4%-9% lower than those of vehicle controls from week 88 to the end of the studies. The survival of the high dose group of male rats was considerably lower than that of the vehicle controls after week 86. No other significant differences in survival were observed between any groups of rats of either sex (male: vehicle control, 28/50; low dose, 20/50, high dose, 2/50; female: 31/50; 30/50; 27/50). Mean body weights of dosed and vehicle control male mice were similar. Mean body weights of high dose female mice were 6%-8% lower than those of vehicle controls from week 40 to week 64 and were 9%-13% lower thereafter. No significant differences in survival were observed between any groups of mice of either sex (male: 36/50; 40/50; 32/50; female: 40/50; 33/50; 38/50). Nonneoplastic and Neoplastic Effects in the Two-Year Studies: The incidence of mononuclear cell leukemia were increased in dosed male rats (vehicle control, 14/50; low dose, 29/50; high dose, 24/50). Follicular cell carcinomas of the thyroid gland in male rats occurred at an increased incidence in low dose male rats (0/49; s of the thyroid gland in male rats occurred at an increased incidence in low dose male rats (0/49; 5/49; 1/49). Reduced survival of high dose male rats may have been responsible for the decreased tumor incidence in this group relative to that in the low dose group. Follicular cell carcinomas were observed in one low dose and one high dose female rat. Follicular cell carcinomas of the thyroid gland have been observed in 3/293 water gavage vehicle control male F344/N rats and in 10/1,904 untreated control male F344/N rats. Adenomas of the nasal cavity were observed in two high dose male rats. Adenomas of the nasal cavity have not been observed in 300 water gavage vehicle control male F344/N rats or in 1,936 untreated control male F344/N rats. Squamous metaplasia and focal atrophy of the salivary glands were observed at increased incidences in dosed rats (squamous metaplasia--male: 0/48; 47/50; 48/49; female:1/49; 48/50; 49/50; focal atrophy--male: 1/48; 10/50; 30/49; female: 0/49; 4/50; 11/50). In dosed female mice, adenomas of the anterior pituitary gland were increased (10/47; 15/45; 24/46). The incidences of adenomas of the harderian gland in dosed female mice were increased (6/50; 8/40; 13/50). A carcinoma of the harderian gland was observed in another high dose female mouse. Dilatation of the thyroid gland follicle and follicular cell hyperplasia were observed at increased incidences in dosed mice (dilatation--male: 0/48; 28/50; 32/50; female: 4/48; 11/48; 10/48; hyperplasia--male: 3/48; 46/50; 34/50; female: 2/48; 25/48; 35/48). The incidences of follicular cell adenomas were 3/48, 6/50, and 0/50 for males and 2/48, 3/48, and 4/48 for females. Hyperkeratosis and acanthosis of the forestomach were observed at increased incidences in high dose male mice (hyperkeratosis: 0/49; 0/49; 5/50; acanthosis: 0/49; 1/49; 5/50). Squamous cell papillomas were observed in female mice (1/49; 2/50; 5/49). The historical incidence of forestomach squamous cell neoplasms is 4/339 (1.2%) in water gavage vehicle control female B6C3F1 mice and is 18/1,994 (0.9%) in untreated control female B6C3F1 mice. Squamous cell neoplasms were not observed in male mice. Genetic Toxicology: Treatment of the base-substitution mutant S. typhimurium strains TA100 and TA1535 with iodinated glycerol in a preincubational protocol with and without S9 resulted in a dose-related increase in the number of revertant colonies; no increase in revertants was observed with the frame-shift mutant strains TA98 or TA1537. 3-Iodo-1,2-propanediol was also mutagenic in TA100 with or without S9; it was not mutagenic in TA98. Iodinated glycerol increased the number of trifluorothymidine-resistant cells in mouse lymphoma L5178Y/TK± assay in the absence of exogenous metabolic activation; it was not tested with activation. Iodinated glycerol induced sister chromatid exchanges (SCEs) and chromosomal aberrations in CHO cells without S9; with S9, the frequency of SCEs was increased more than without S9 but no chromosomal aberrations were induced. No increase in micronucleated polychromatic erythrocytes was observed in the bone marrow of B6C3F1 mice after injection with either iodinated glycerol or 3-iodo-1,2-propanediol. Conclusions: Under the conditions of these 2-year gavage studies, there was some evidence of carcinogenic activity for male F344/N rats administered iodinated glycerol, as indicated by increased incidences of mononuclear cell leukemia and follicular cell carcinomas of the thyroid gland. Adenomas of the nasal cavity in two high dose male rats may have been related to the administration of iodinated glycerol. There was no evidence of carcinogenic activity for female F344/N rats administered 62 or 125 mg/kg iodinated glycerol by gavage for 103 weeks. There was no evidence of carcinogenic activity for male B6C3F1 mice administered 125 or 250 mg/kg iodinated glycerol by gavage for 103 weeks. There was some evidence of carcinogenic activity for female B6C3F1 mice administered iodinated glycerol, as indicated by increased incidences of adenomas of the anterior pituitary gland and neoplasms of the harderian gland. Squamous cell papillomas of the forestomach may have been related to the administration of iodinated glycerol. Significant nonneoplastic lesions considered related to exposure of iodinated glycerol were squamous metaplasia and focal atrophy of the salivary gland in male and female rats. Dilatation of the thyroid gland follicle and follicular cell hyperplasia were observed in male and female mice. Synonyms or Trade Names: Organidin®.; iodopropylidene glycerol
对碘化甘油(Organidin®,一种由碘与甘油反应制备的复杂混合物,主要成分是33%的3 - 碘 - 1,2 - 丙二醇)进行了毒理学和致癌性研究,因为人体会接触到作为祛痰剂的碘化甘油,且它可能与烷基碘(如甲基碘,一种可疑的动物致癌物)的形成有关。这些研究通过每周5天经口灌胃给予F344/N大鼠和B6C3F1小鼠不同剂量的碘化甘油水溶液进行,持续16天、13周或2年。使用碘化甘油对鼠伤寒沙门氏菌、小鼠L5178Y淋巴瘤细胞、中国仓鼠卵巢(CHO)细胞以及B6C3F1小鼠(体内骨髓微核试验)进行了遗传毒理学研究。此外,还对3 - 碘 - 1,2 - 丙二醇在鼠伤寒沙门氏菌和B6C3F1小鼠(体内微核试验)中进行了测试。
16天和13周研究:对大鼠给予高达1000 mg/kg剂量、对小鼠给予高达500 mg/kg剂量的碘化甘油进行了16天的研究。最高剂量组的所有雌性大鼠和4/5的雄性小鼠在研究结束前死亡;研究结束时,雄性或雌性大鼠以及雄性小鼠的体重未出现与剂量相关的影响。接受500 mg/kg剂量的2/5雌性小鼠的前胃增厚且呈颗粒状。对大鼠和小鼠给予高达500 mg/kg剂量的碘化甘油进行了13周的研究。在这些研究中,接受500 mg/kg剂量的3/10雌性大鼠和1/10雌性小鼠死亡。接受500 mg/kg剂量的大鼠和小鼠的最终平均体重,雄性比溶媒对照组低4%,雌性低6% - 7%。在最高剂量组的雌性大鼠中,观察到肾小管细胞病变(包括皮质坏死、再生和钙化)的发生率增加。在给药的雄性和雌性大鼠中均观察到胃淋巴组织增生。在给药的雌性小鼠中也观察到肾小管细胞再生。在最高剂量组的雌性小鼠的前胃中观察到轻度至中度的炎症或脓肿以及轻度至中度的增生、棘皮症和/或角化过度。
对50只雄性F344/N大鼠和50只雄性B6C3F1小鼠,每周5天经口灌胃给予0、125或250 mg/kg碘化甘油于去离子水中,持续103周,进行了两年的研究。由于在13周研究中肾脏和胃部病变的严重程度增加,对50只雌性F344/N大鼠和50只雌性B6C3F1小鼠,以0、62或125 mg/kg的较低剂量按相同时间表给予碘化甘油。从第43周到第68周,高剂量雄性大鼠的平均体重比溶媒对照组低5% - 10%,从第72周到研究结束低10% - 13%。从第88周到研究结束,低剂量雄性大鼠和高剂量雌性大鼠的平均体重比溶媒对照组低4% - 9%。高剂量组雄性大鼠在第86周后的存活率显著低于溶媒对照组。在任何性别大鼠组之间未观察到其他显著的存活率差异(雄性:溶媒对照组,28/50;低剂量组,20/50;高剂量组,2/50;雌性:31/50;30/50;27/50)。给药雄性小鼠和溶媒对照组雄性小鼠的平均体重相似。从第40周到第64周,高剂量雌性小鼠的平均体重比溶媒对照组低6% - 8%,此后低9% - 13%。在任何性别小鼠组之间未观察到显著的存活率差异(雄性:36/50;40/50;32/50;雌性:40/50;33/50;38/50)。
给药雄性大鼠中单核细胞白血病的发生率增加(溶媒对照组,14/50;低剂量组:29/50;高剂量组:24/50)。低剂量雄性大鼠甲状腺滤泡细胞癌的发生率增加(0/49;溶媒对照组;5/49;低剂量组;1/49;高剂量组)。高剂量雄性大鼠存活率降低可能是该组肿瘤发生率低于低剂量组的原因。在一只低剂量和一只高剂量雌性大鼠中观察到甲状腺滤泡细胞癌。在3/293只经水灌胃的溶媒对照组雄性F344/N大鼠和10/1904只未经处理的对照雄性F344/N大鼠中观察到甲状腺滤泡细胞癌。在两只高剂量雄性大鼠中观察到鼻腔腺瘤。在300只经水灌胃的溶媒对照组雄性F344/N大鼠或1936只未经处理的对照雄性F344/N大鼠中未观察到鼻腔腺瘤。给药大鼠唾液腺鳞状化生和局灶性萎缩的发生率增加(鳞状化生 -
0/48;溶媒对照组;47/50;低剂量组;48/49;高剂量组;雌性:1/49;溶媒对照组;48/50;低剂量组;49/50;高剂量组;局灶性萎缩 - 雄性:1/48;溶媒对照组;10/50;低剂量组;30/49;高剂量组;雌性:0/49;溶媒对照组;4/50;低剂量组;11/50;高剂量组)。在给药雌性小鼠中,垂体前叶腺瘤增加(10/47;溶媒对照组;15/45;低剂量组;24/46;高剂量组)。给药雌性小鼠哈德氏腺腺瘤的发生率增加(6/50;溶媒对照组;8/4(此处原文可能有误,推测为8/40);低剂量组;13/50;高剂量组)。在另一只高剂量雌性小鼠中观察到哈德氏腺癌。给药小鼠甲状腺滤泡扩张和滤泡细胞增生的发生率增加(扩张 - 雄性:0/48;溶媒对照组;28/50;低剂量组;32/50;高剂量组;雌性:4/48;溶媒对照组;11/48;低剂量组;10/48;高剂量组;增生 - 雄性:3/48;溶媒对照组;46/50;低剂量组;34/50;高剂量组;雌性:2/48;溶媒对照组;25/48;低剂量组;35/48;高剂量组)。雄性滤泡细胞腺瘤的发生率分别为3/48、6/50和0/50,雌性分别为2/48、3/48和4/48。高剂量雄性小鼠前胃角化过度和棘皮症的发生率增加(角化过度:0/49;溶媒对照组;0/49;低剂量组;5/50;高剂量组;棘皮症:0/49;溶媒对照组;1/49;低剂量组;5/50;高剂量组)。在雌性小鼠中观察到鳞状细胞乳头瘤(1/49;溶媒对照组;2/50;低剂量组;5/49;高剂量组)。在经水灌胃的溶媒对照组雌性B6C3F1小鼠中,前胃鳞状细胞肿瘤的历史发生率为4/339(1.2%),在未经处理的对照雌性B6C3F1小鼠中为18/1994(0.9%)。在雄性小鼠中未观察到鳞状细胞肿瘤。
在预孵育方案中,用碘化甘油处理碱基置换突变型鼠伤寒沙门氏菌菌株TA100和TA1535,无论有无S9,均导致回复菌落数呈剂量相关增加;用移码突变菌株TA98或TA1537处理未观察到回复菌落增加。3 - 碘 - 1,2 - 丙二醇在有或无S9的情况下对TA100也具有致突变性;对TA98无致突变性。在无外源性代谢激活的情况下,碘化甘油增加了小鼠淋巴瘤L(此处原文可能有误,推测为L5178Y)/TK±试验中三氟胸苷抗性细胞的数量;未进行有激活情况下的测试。碘化甘油在无S9的情况下诱导CHO细胞中的姐妹染色单体交换(SCE)和染色体畸变;有S9时,SCE频率比无S9时增加更多,但未诱导染色体畸变。给B6C3F1小鼠注射碘化甘油或3 - 碘 - 1,2 - 丙二醇后,在其骨髓中未观察到微核多染红细胞增加。
在这些为期两年的灌胃研究条件下,有一些证据表明给予碘化甘油的雄性F344/N大鼠具有致癌活性,表现为单核细胞白血病和甲状腺滤泡细胞癌的发生率增加。两只高剂量雄性大鼠的鼻腔腺瘤可能与给予碘化甘油有关。对经口灌胃103周给予62或125 mg/kg碘化甘油的雌性F344/N大鼠,没有致癌活性的证据。对经口灌胃103周给予